Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis

Arthritis Rheum. 1996 Feb;39(2):287-91. doi: 10.1002/art.1780390217.


Objective: To determine the usefulness of measuring sensitive markers of the coagulation-fibrinolysis system (i.e., thrombin-antithrombin III complex [TAT], D dimer fragments [DD], and plasmin-alpha2-plasmin inhibitor complex [PIC]) for evaluating disease activity in patients with systemic lupus erythematosus (SLE).

Methods: We studied 57 SLE patients. Plasma concentrations of DD were measured by latex agglutination using monoclonal antibodies; TAT and PIC were determined by sandwich enzyme-linked immunosorbent assay. Disease activity was determined by using the SLE Disease Activity Index (SLEDAI).

Results: Levels of TAT, DD, and PIC were higher in SLE patients than in healthy controls (P<0.05). Levels of TAT and DD showed good correlations with SLEDAI scores (for TAT r=0.66, P<0.001; for DD r=0.50, P<0.001). Elevated levels of TAT, DD, and PIC were decreased following treatment.

Conclusion: These results strongly suggest that measurement of molecular markers of hemostasis is useful for evaluating disease activity in patients with SLE.

MeSH terms

  • Adult
  • Antifibrinolytic Agents / metabolism
  • Antithrombin III / metabolism
  • Betamethasone / therapeutic use
  • Biomarkers
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Fibrinolysin / metabolism
  • Hemostasis*
  • Humans
  • Lupus Erythematosus, Systemic / blood*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / physiopathology
  • Methylprednisolone / therapeutic use
  • Partial Thromboplastin Time
  • Peptide Hydrolases / metabolism
  • Prothrombin Time
  • alpha-2-Antiplasmin*


  • Antifibrinolytic Agents
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • alpha-2-Antiplasmin
  • antithrombin III-protease complex
  • plasmin-plasmin inhibitor complex
  • Antithrombin III
  • Betamethasone
  • Peptide Hydrolases
  • Fibrinolysin
  • Methylprednisolone